Angioimmunoblastic lymphadenopathy. Long-term follow-up study

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) is a rare T-cell lymphoproliferative disorder.
• Long-term outcomes and prognostic factors for AILD remain incompletely understood.

Purpose of the Study:

• To describe the long-term clinical course of patients with AILD.
• To identify factors associated with survival in AILD.

Main Methods:

• Retrospective analysis of 41 previously reported AILD patients with at least five years of follow-up.
• Evaluation of complete remission (CR) rates, duration of CR, survival, and potential prognostic factors including chemotherapy regimens and lymphocytopenia.

Main Results:

• 27 out of 41 patients achieved a complete remission (CR), with a median CR duration of 48 months.
• Patients achieving CR had a significantly longer median survival (51 months) compared to those with partial or no response (9 months).
• A trend suggested improved survival with combination chemotherapy including prednisone; lymphocytopenia was more common in deceased patients.

Conclusions:

• Achieving complete remission is strongly associated with improved long-term survival in AILD.
• Prognosis in AILD is significantly influenced by response to treatment and the presence of lymphocytopenia.